{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T02:07:24Z","timestamp":1772935644851,"version":"3.50.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/cad.0000000000000048","type":"journal-article","created":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T16:03:21Z","timestamp":1386086601000},"page":"315-322","source":"Crossref","is-referenced-by-count":11,"title":["Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells"],"prefix":"10.1097","volume":"25","author":[{"given":"Xiaodi","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibo","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Che","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinglei","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210203","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"R2-9-20210203","first-page":"471","article-title":"Stomach cancer incidence in the world.","volume":"31","author":"Yamamoto","year":"2001","journal-title":"Jpn J Clin Oncol"},{"key":"R4-9-20210203","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.","volume":"19","author":"Gravalos","year":"2008","journal-title":"Ann Oncol"},{"key":"R8-9-20210203","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canlet.2004.04.029","article-title":"Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.","volume":"214","author":"Gong","year":"2004","journal-title":"Cancer Lett"},{"key":"R9-9-20210203","first-page":"681","article-title":"Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.","volume":"27","author":"Matsui","year":"2005","journal-title":"Int J Oncol"},{"key":"R10-9-20210203","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00280-006-0337-z","article-title":"Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.","volume":"59","author":"Fujimoto-Ouchi","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"R13-9-20210203","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.critrevonc.2006.02.003","article-title":"The development of platinum compounds and their possible combination.","volume":"60","author":"Pasetto","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"R14-9-20210203","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s10120-011-0007-7","article-title":"Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis.","volume":"14","author":"Montagnani","year":"2011","journal-title":"Gastric Cancer"},{"key":"R15-9-20210203","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000323345","article-title":"Trastuzumab plus chemotherapy in gastric cancer overexpressing HER-2 and EGFR: a case report.","volume":"34","author":"Al-Batran","year":"2011","journal-title":"Onkologie"},{"key":"R16-9-20210203","first-page":"1","article-title":"Oxaliplatin pharmacokinetics and chronopharmacological aspects.","volume":"38","author":"Levi","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"R17-9-20210203","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0093-7754(01)90276-3","article-title":"Mechanism of action of trastuzumab and scientific update.","volume":"28","author":"Baselga","year":"2001","journal-title":"Semin Oncol"},{"key":"R18-9-20210203","first-page":"2093","article-title":"Cell cycle arrest and apoptosis induced by oxaliplatin (L-OHP) on four human cancer cell lines.","volume":"26","author":"William-Faltaos","year":"2006","journal-title":"Anticancer Res"},{"key":"R19-9-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2005.01.041","article-title":"Herceptin: mechanisms of action and resistance.","volume":"232","author":"Nahta","year":"2006","journal-title":"Cancer Lett"},{"key":"R22-9-20210203","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.critrevonc.2004.08.008","article-title":"Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.","volume":"53","author":"Chaney","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"R23-9-20210203","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0305-7372(98)90056-1","article-title":"Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.","volume":"24","author":"Reed","year":"1998","journal-title":"Cancer Treat Rev"},{"key":"R27-9-20210203","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0959-8049(02)00411-2","article-title":"Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.","volume":"39","author":"Arnould","year":"2003","journal-title":"Eur J Cancer"},{"key":"R29-9-20210203","first-page":"5970","article-title":"In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.","volume":"53","author":"Pendyala","year":"1993","journal-title":"Cancer Res"},{"key":"R30-9-20210203","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/10715769900301121","article-title":"Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells.","volume":"31","author":"Goto","year":"1999","journal-title":"Free Radic Res"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0000000000000048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:01:21Z","timestamp":1620946881000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-201403000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0000000000000048","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}